Consultant | Auckland
Shelley works with clients to obtain patent protection for their new innovations.
Shelley’s experience spans advising clients on intellectual property policy and strategy, securing protection for new innovations, managing IP portfolios, challenges to the validity of patent applications and advising on intellectual property infringement matters. She has particular expertise in molecular biology, biochemistry, genetics and immunology. Her clients operate in a broad range of industries, including clean technology, agriculture, horticulture, human and animal health, and pharmaceuticals.
Before she became a patent attorney, Shelley conducted medical research at the University of Auckland Medical School, which focussed on the molecular aspects of multiple sclerosis. Her earlier MSc research looked at the molecular and genetic aspects of a human neurological disorder (Adrenoleukodystrophy). Through this work she developed a diagnostic test for the disorder, which piqued an interest in intellectual property.
Shelley has a particular interest in working with clients to ensure their intellectual property policy and strategy aligns with their commercial goals. She has an Master of Management degree, which focussed on new ventures and the entrepreneurial process. In her spare time, Shelley enjoys the outdoors and competes in a variety of swimming events. She has been a New Zealand record holder in butterfly.
Shelley is a past partner of the firm and became a consultant at Baldwins in April 2015.
- IP policy and strategy
- IP portfolio management
- Patent filing and examination
- Patent oppositions and revocations
- Biotechnology, genetics, physiology
- Human and animal health including pharmaceuticals, biologics, nutraceuticals, diagnostics
- Clean technology
- Registered Patent Attorney (New Zealand and Australia)
- 2009 Master of Management, University of Auckland
- 1995 Master of Science (1st Class Hons), University of Auckland
- 1992 Bachelor of Science, University of Auckland
Awards & Recognition
Articles by Shelley Rowland
- 05 08 2016The end of a long campaign – Supreme Court denies Sequenom’s petition
- 06 07 2016USPTO Cancer Immunotherapy Pilot Program
- 30 09 2014Full Federal Court confirms isolated genes to remain patent eligible in Australia
- 28 08 2014MORGO2014
- 11 07 2014Law Reforms Influence Demand for Patents Down Under
- 25 06 2014Isolated Nucleic Acids are Patent Eligible in Australia
- 16 06 2014Expediting Patent Examination in Australia
- 10 06 2014Significant Changes to New Zealand Patents Act – Benefits to Filing Applications before 13 September
- 05 02 2014Extending your European Patent Term. When is a product a protected product?
- 01 02 2014Funding for Early-Stage Start-Ups. MBIE Accelerator Programme – Applications Closing Soon!
- 29 01 2014Security Interests Registered at IP Australia Must Migrate to PPSR by 31 January 2014
- 24 01 2014EPO Removes 2-Year Deadline for Filing Divisional Applications
- 13 12 2013Who’s that walking over my bridge?: United States Congress gets gruff with patent trolls
- 12 10 2013Delays in patent examination in Australia
- 12 09 2013Micro-organisms to Remain Patentable Subject Matter in New Patents Act
- 25 07 2013Government’s ‘Better by …’ programme expanded to address one of the key issues
- 15 07 2013Callaghan Innovation: One step closer to being out of the lab and into the marketplace
- 05 06 2013Third party observations for pending PCT applications
- 26 02 2013USPTO Publishes Final Guidelines for New America Invents Act
- 13 02 2013United States switches from first-to-invent to first-inventor-to-file system in 2013
- 18 01 2013Isolated DNA patent-eligible, comparison methods maybe not: Myriad unchanged by Mayo (so far)
- 18 01 2013India’s IP Appellate Board endorses compulsory license of patented cancer drug
- 18 01 2013The Patent Box – Tax reductions for patent-protected products in the UK
- 18 01 2013Callaghan Innovation: A new Advanced Technology Institute for New Zealand